SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
一般交易時段
US$19.5449
+US$0.1749 · +0.90%
盤中時間採用ET。市場資料可能有所延遲。
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
日內區間
目前US$19.5449
52週區間
目前US$19.5449
盤中時間採用ET。市場資料可能有所延遲。
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
日內區間
目前US$19.5449
52週區間
目前US$19.5449
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.01億 USD | 1.67億 USD | 1.39億 USD | 1.06億 USD | 9015.2萬 USD |
| 銷貨成本 | 4104.7萬 USD | 3505.7萬 USD | 2946.6萬 USD | 1570.5萬 USD | 1042.8萬 USD |
| 毛利 | 1.6億 USD | 1.32億 USD | 1.09億 USD | 9070.4萬 USD | 7972.4萬 USD |
| 研究與開發 | 1744.8萬 USD | 1656萬 USD | 1502.8萬 USD | 1362.7萬 USD | 1244.1萬 USD |
| 銷售、一般及管理費用 | 1.65億 USD | 1.51億 USD | 1.41億 USD | 1.37億 USD | 1.19億 USD |
| 營業費用 | 1.82億 USD | 1.67億 USD | 1.56億 USD | 1.5億 USD | 1.31億 USD |
| 利息收入 | 607.3萬 USD | 784.8萬 USD | 691.6萬 USD | 130.4萬 USD | 18.6萬 USD |
| 利息支出 | 528.3萬 USD | 344萬 USD | 346.2萬 USD | 281.9萬 USD | 536.5萬 USD |
| 折舊和攤銷 | 271.9萬 USD | 437.9萬 USD | 542.8萬 USD | 345.2萬 USD | 208.6萬 USD |
| 營業利益 | −2233萬 USD | −3524.8萬 USD | −4693.1萬 USD | −5960.9萬 USD | −5167萬 USD |
| 淨利 | −1890.8萬 USD | −3091.3萬 USD | −4333.6萬 USD | −6125.6萬 USD | −5657.2萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動,並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。